DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of multiple myeloma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities in specific lines of therapy are forecast for the developed world.

DRG Epidemiology’s multiple myeloma forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with multiple myeloma per year?
  • Of all people diagnosed with multiple myeloma, how many in each country in the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of multiple myeloma over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following multiple myeloma patient populations:

  • Diagnosed incident cases.
  • Diagnosed incident cases by stage distribution.
  • Diagnosed incident cases by symptomatic status.
  • First-line drug-treatable population.
  • First-line drug-treatable population by transplant-eligibility status.
  • First-line transplant-eligible drug-treatment subpopulation(s).
  • First-line transplant-ineligible drug-treatment subpopulation(s).
  • Second-line drug-treatable subpopulation(s).
  • Diagnosed incident cases of monoclonal gammopathy of undetermined significance (MGUS).
  • Total prevalent cases of MGUS.

… and more (details available on request).

Note: Coverage may vary by country and region.

Table of contents

  • Multiple Myeloma - Epidemiology - Emerging Markets
    • Introduction
      • Key Findings
      • Key Updates
      • Incidence of Multiple Myeloma per 100,000 per Year Among People of All Ages in 2020 and 2030
      • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Multiple Myeloma over the Next Ten Years
      • Analysis of Diagnosed Incident Cases of Multiple Myeloma Across the Countries Under Study in 2020 by Scheme name, e.g. "Severity"
      • Analysis of the Incident Cases of Multiple Myeloma in 2020 by Diagnosed and Drug-Treated Status
      • Number of Additional Incident Cases of Multiple Myeloma Incurred over 2020-2030 in the Countries Under Study due to Trends in Risk
      • Number of Additional Incident Cases of Multiple Myeloma Incurred over 2020-2030 in the Countries Under Study due to Trends in Risk
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases of Multiple Myeloma
      • ISS Stage Distribution
      • Diagnosed Incident Cases of Multiple Myeloma by Symptoms
      • Diagnosed Prevalent Cases
      • Progression of Asymptomatic Multiple Myeloma to Symptomatic Multiple Myeloma
      • Lifetime DALYs Gained
      • Drug-Treatable Populations and Percentage Drug-Treated
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Multiple Myeloma
        • Studies Excluded from the Analysis of Multiple Myeloma
      • Risk/Protective Factors
        • Risk/Protective Factors for Multiple Myeloma
      • Bibliography
      • Glossary

Author(s): Atul Sharma, M.P.H.; Nishant Kumar, M.P.H.

Atul Sharma, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. He holds a master’s degree in public health from the School of Public Health, Post-Graduate Institute of Medical Education and Research, and a bachelor’s degree in dental surgery from MN DAV Dental College and Hospital.

Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.


Related Reports

Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed...

View Details

Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

View Details

Multiple Myeloma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

View Details

Multiple Myeloma - Epidemiology - Americas

DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in...

View Details